Quintrio
Home

ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES

Conexeu Sciences Inc. Common Stock

CNXU

Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.

Last trade $2.02
Day change -$0.19 (-8.60%)
Day range $1.99 – $2.40
Volume 155,700
Market cap $68M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for CNXU.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for CNXU.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Investing.com

Before the IPO: 4 Companies That Rewarded Investors Who Got In Early

Analyst Chris Graebe highlights four private companies that delivered substantial returns to early investors before going public: Starfighters Space (FJET) with a 7x return, BeatBox Beverages with a 5-6x return via acquisition, Eagle Nuclear Energy Corp. (NUCL) with a 4x peak return, and Conexeu Sciences Inc. (CNXU) with an 8x return. The article emphasizes that the biggest IPO gains typically accrue to early private investors, not those entering at public listing, and discusses the JOBS Act's Regulation A offerings as a pathway for retail investors to access pre-IPO opportunities.

Benzinga

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It

Conexeu Sciences Inc. (CNXU) commenced trading on Nasdaq on May 21, 2026, as a regenerative tissue platform company. The company's proprietary CXU™ extracellular matrix platform is designed to scale across multiple markets including wound care, breast reconstruction, and aesthetic medicine without reformulation. The company targets a 510(k) submission in early 2027 and holds issued patents across major markets with no royalty obligations.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.